Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Institute of Hematology "L. e A. Seragnòli", Bologna, Italy.
Expert Rev Hematol. 2013 Oct;6(5):563-74. doi: 10.1586/17474086.2013.837279. Epub 2013 Oct 2.
The median age at diagnosis of chronic myeloid leukemia (CML) is between 60 and 65 years in most epidemiologic registries. Rather than age per se, a comprehensive evaluation of comorbidities may describe more properly the general clinical status of a patient. Tyrosine-kinase inhibitors (TKIs) have a different tolerability profile, and some adverse events (AEs) are peculiar of each drug, in particular, in presence of predisposing factors (comorbidities, concomitant medications). This article will review the impact of comorbidities in the safety and outcome of CML patients treated with TKIs. We will explore how the comorbidity status may be considered, together with CML-related factors, in the selection of the TKI in order to optimize treatment.
在大多数流行病学登记处，慢性髓性白血病（CML）的诊断中位年龄在 60 至 65 岁之间。全面评估合并症可能比年龄本身更能准确描述患者的一般临床状况。酪氨酸激酶抑制剂（TKI）具有不同的耐受性特征，某些不良反应（AE）是每种药物所特有的，特别是在存在易患因素（合并症、合并用药）的情况下。本文将综述合并症对接受 TKI 治疗的 CML 患者安全性和结局的影响。我们将探讨如何在选择 TKI 时，将合并症状况与 CML 相关因素一起考虑，以优化治疗。
